What You Should Know About Ibuprofen Hasco
Ibuprofen Hasco is a non-steroidal anti-inflammatory drug (NSAID) that is approved by the FDA to treat a variety of conditions, including headaches, migraines, period pain, and rheumatic pain. It is available in tablet and capsule form. Before using this medication, you should know the potential risks associated with it, such as gastrointestinal bleeding, liver disorders, and hepatotoxicity. Some patients have reported NSAIDs to increase their risk of bleeding. You can avoid these complications by following a few important guidelines.
Patients with a history of peptic ulcer should not take Ibuprofen Hasco. NSAIDs can also cause hepatotoxicity, which can increase the risk of CV events. The chance of developing hepatotoxicity without warning signs is greater when you take low-dose NSAIDs. Therefore, you should keep an eye on your blood pressure and be vigilant for symptoms. If you notice any symptoms of hepatotoxicity, you should stop taking the drug and consult with your doctor.
Preterm infants should be treated with extra caution. Studies have found that preterm newborns who are given ibuprofen are more likely to have a patent ductus arteriosus. This occurs when a ductus arteriosus is not closed in a timely manner. There are several options for closing the ductus arteriosus, including surgery. In addition, Ibuprofen can also inhibit platelet aggregation, which can lead to bleeding. To minimize the risk of this adverse effect, it is recommended that you not give Ibuprofen Hasco to premature newborns.
The primary dose of Ibuprofen Hasco is 10 mg per kilogram of body weight. Subsequent doses are 5 mg per kilogram. The first dose should be administered after six hours of life. Administer the medication via the nearest insertion site. During the first six hours of life, the fetal ductus arteriosus may close. After this time, a second course of Ibuprofen Hasco may be required. Unless a second course is necessary, the medication should be discontinued when the ductus arteriosus is reopening.
When administering parenteral drug products, you should visually inspect the drug for any particulate matter. If any particulate matter is observed, you should discontinue use and consider alternate therapies. NSAIDs may also increase the risk of bleeding, especially in the presence of antiplatelet agents and serotonin reuptake inhibitors. Your healthcare provider may require a CBC during your NSAID therapy.
While there have been reports of mild hypersensitivity reactions, such as abdominal pain and nausea, severe hypersensitivity reactions can cause facial swelling, dyspnea, and even shock. Depending on the underlying condition, these adverse reactions can be serious. Those experiencing these symptoms should seek emergency medical attention. Other serious adverse reactions can include aseptic meningitis, abdominal pain, and liver damage.
Patients with a history of aspirin sensitivity should be carefully monitored for bleeding and GI ulcers. They should not be given ibuprofen unless their physician feels it is appropriate. A small subpopulation of asthmatics is aspirin-sensitive. Symptoms of aspirin-sensitive asthma can include chronic rhinosinusitis, nasal polyps, and severe, potentially fatal bronchospasm. For more information, visit the National Aspirin Information Center at www.naic.org.
